Download the new version of our App with the latest Pocket Guidelines for professionals and Guides for Patients. The ESMO Advanced Courses aim to address specific therapeutic challenges in patient management in different tumour settings. These annual five-day residential courses enable students to get a full picture of this challenging and interesting professional field before making the choice of their specialisation.
The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. ESMO fosters the advancement of cancer research by supporting clinical trials workshops to inspire young oncologists from different disciplines across the globe to become the next generation of active researchers.
Invest in your future and the future of cancer care. Learn more about our Oncology Fellowship Programme. An exciting, intensive course designed for the future leaders in our profession and our society. Apply by 7 January ! An exciting, intensive course designed for the future leaders in our profession in the Asia-Pacific region.
General European grant scheme information highlighting the main objectives, available funding and target audiences. Guides for Patients are designed to assist patients, their relatives and caregivers to better understand the nature of different types of cancer and evaluate the best available treatment choices.
Video interviews and articles designed to help patients, policy makers and other non-medical professionals better understand the principles of personalised cancer medicine. Now available in Romanian, our Guide for Patients with Advanced Cancer is designed for patients, their family members and oncologists. The objective of this ESMO-led study is to provide health authorities with data on the availability of licensed anti-neoplastic medicines.
ESMO seeks to eradicate cancer at its earliest stages through effective cancer prevention awareness and advocacy campaigns. Rare Cancers Europe is a multi-stakeholder initiative dedicated to putting rare cancers firmly on the European policy agenda. Dreyling, M. Ghielmini, S. From Wikipedia, the free encyclopedia. Specialty Hematology and oncology Diffuse large B-cell lymphoma is a cancer of B cells , a type of white blood cell responsible for producing antibodies. British Journal of Cancer. British Journal of Haematology. Elsevier Health Sciences. In Basow, DS ed. Journal of Clinical Oncology.
Cancer Control. Bibcode : Natur. Nature Medicine. New England Journal of Medicine. Proceedings of the National Academy of Sciences. Bibcode : PNAS.. Journal of Clinical Pathology. Clinical Cancer Research. The Journal of Pathology. Annual Review of Pathology. Human Pathology. Contemporary Oncology. The Journal of Hematology Oncology Pharmacy. American Society of Hematology. Education Program. The Oncologist. Retrieved Lancet Haematology. Nature Genetics. ICD - 10 : C Diffuse large B-cell lymphoma Intravascular large B-cell lymphoma Primary cutaneous marginal zone lymphoma Primary cutaneous immunocytoma Plasmacytoma Plasmacytosis Primary cutaneous follicle center lymphoma.
Hepatosplenic Angioimmunoblastic Enteropathy-associated T-cell lymphoma Peripheral T-cell lymphoma not otherwise specified Lennert lymphoma Subcutaneous T-cell lymphoma. Lymphoid proliferations associated with human immunodeficiency virus infection. Hamilton-Dutoit, S.
Epstein—Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Touitou, R. Dunleavy, K. Gaidano, G.
Tirelli, U. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of patients from the Italian Cooperative Group on AIDS and Tumors. Biggar, R. Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity? HIV-associated Hodgkin's lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity. Markers 22 , — Deeken, J. Novak, R.
Immune reconstitution inflammatory syndrome: incidence and implications for mortality. AIDS 26 , — Rajasuriar, R. Persistent immune activation in chronic HIV infection: do any interventions work? Kowalkowski, M. Vega, F. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Pantanowitz, L. Differentiating HIV-associated non-Hodgkin's lymphomas with similar plasmacellular differentiation.
HIV Ther. Editorial comment: hemophagocytic syndrome—an HIV-associated quagmire. AIDS Read. Stein, H. Knowles, D. Delecluse, H.
Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 89 , — Gatter, K. Castillo, J. HIV-associated plasmablastic lymphoma: lessons learned from published cases. An Emergent Disease with Poor Prognosis ed. Colomo, L. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Jung, C. Uncommon hematologic malignancies. Case 1. Plasmablastic leukemia in HIV-associated multicentric Castleman's disease.
Goedhals, J. The ultrastructural features of plasmablastic lymphoma.
Reid-Nicholson, M. Plasmablastic lymphoma: cytologic findings in 5 cases with unusual presentation.
Bogusz, A. Is plasmablastic lymphoma of the oral cavity an HHVassociated disease? Seliem, R. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. Klein, U. Morassut, S. HIV-associated human herpesvirus 8-positive primary lymphomatous effusions: radiologic findings in six patients.
Radiology , — Katano, H. Human herpesvirus 8-associated solid lymphomas that occur in AIDS patients take anaplastic large cell morphology. Pan, Z. Extracavitary KSHV-associated large B-cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases. Extracavitary KSHV-positive solid lymphoma: a large B-cell lymphoma within the spectrum of primary effusion lymphoma. Fend, F. Early lesions in lymphoid neoplasia.
Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS 14 , — Mounier, N. Modern management of non-Hodgkin lymphoma in HIV-infected patients. State of the art oncology in Europe. Staroncology [online] , Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection.
Ratner, L. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. AIDS-related non-Hodgkin lymphoma: final analysis of patients treated with risk-adapted intensive chemotherapy. Sparano, J. Little, R. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Levine, A. Management of AIDS-related lymphoma. How I treat HIV-associated lymphoma. Spina, M.
View this table: In this window In a new window. Burkitt lymphoma. Termination of pregnancy in the first trimester may be an option that allows immediate therapy for women with aggressive NHL. The Journal of Hematology Oncology Pharmacy. Our open library offers over 80 modules!
Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Boue, F.
Ribera, J. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Lim, S. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
Miralles, P. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. Antinori, A. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.
Update Ministero della salute. National comprehensive cancer network [online]. Rudek, M. Pham, P.
Lymphoma: Diagnosis and Treatment (Current Clinical Oncology Book 43) eBook: Anas Younes, Bertrand Coiffier: eziwaganyd.tk: Kindle Store. Current Clinical Oncology Diagnosis and Treatment Easy to use, high-yield format features each type of lymphoma in an individual chapter; Each chapter.
Emerging antiretroviral drug interactions. Zolopa, A.
Cancer 37 , — Re, A. Diez-Martin, J. Balsalobre, P. Autologous stem-cell transplantation in patients with HIV-related lymphoma. Krishnan, A. Blood Marrow Transplant. Michieli, M. Stem cell transplantation for lymphoma patients with HIV infection. Cell Transplant. Bayraktar, U. Lymphoma 53 , — Noy, A. Galicier, L. Wang, E. Cancer 98 , — Blood , a Implications of the shifting pathobiology of AIDS-related lymphoma. Simonelli, C.
Prognostic factors in human herpesvirus 8-related lymphoproliferative disorders associated with HIV infection. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Reid, E.